“The main finding of the study was that, like…other clinical trial studies in the past, we also found that there was an over representation of non-Hispanic White patients in these trials, and a dramatic under representation of people traditionally and historically underrepresented in clinical trials and in medicine,” says Kevin Koo, MD, MPH.
In this video, Kevin Koo, MD, MPH, discusses the background and notable findings from the study, “Disparities in race and ethnicity reporting in contemporary clinical trials leading to new drug approvals in urology,” which was presented at the North Central Section of the American Urological Association Annual Meeting in Chicago, Illinois. Koo is a urologist at Mayo Clinic in Rochester, Minnesota.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.